Vancomycin-Resistant Enterococci-An Updated Review for Pharmacists and Medical Secretary.

Background: Vancomycin-resistant Enterococci (VRE) represent a significant challenge in hospital settings, contributing to increased morbidity, mortality, and healthcare costs. Enterococci are normally harmless gut commensals but can become pathogenic under certain conditions, leading to infections such as urinary tract infections (UTIs), bacteremia, endocarditis, and intra-abdominal infections. VRE, particularly strains of Enterococcus faecium, have developed resistance to vancomycin, complicating treatment options and requiring focused antimicrobial stewardship. Aim: This review provides an updated overview of VRE, focusing on its etiology, resistance mechanisms, epidemiology, clinical manifestations, and treatment strategies, with particular emphasis on the role of pharmacists in managing these infections. The review also focus on the main role of medical records in documentation of this issue. Methods: A comprehensive review of current literature was conducted to examine the mechanisms of resistance in Enterococci, the clinical impact of VRE infections, and the available therapeutic options. The review also highlights the role of pharmacists in optimizing antimicrobial therapy and infection control practices. Results: VRE infections are primarily caused by E. faecium, which exhibits high resistance to vancomycin and other antimicrobial agents. Resistance mechanisms, including modifications in cell wall synthesis, complicate treatment regimens. Pharmacists play a key role in selecting appropriate antibiotics, optimizing dosages, and providing infection control advice. The use of linezolid and daptomycin is recommended for managing VRE infections, with careful monitoring of adverse effects. Conclusion: The increasing prevalence of VRE necessitates comprehensive strategies involving surveillance, targeted therapy, and robust infection control. Pharmacists are essential in guiding appropriate treatment choices, monitoring therapeutic efficacy, and mitigating adverse effects, ultimately improving patient outcomes.